Adverum Biotechnologies (ADVM) News Today $3.49 +0.16 (+4.80%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$3.49 0.00 (0.00%) As of 05/2/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Adverum Biotechnologies Grants Inducement Awards to New Employees Under 2017 Inducement PlanMay 4 at 2:29 PM | nasdaq.comAdverum Biotechnologies (ADVM) Expected to Announce Quarterly Earnings on ThursdayAdverum Biotechnologies (NASDAQ:ADVM) will be releasing its Q4 2024 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-adverum-biotechnologies-inc-stock/)May 3 at 5:46 AM | marketbeat.comAdverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2 at 4:01 PM | globenewswire.comTCG Crossover Management LLC Cuts Position in Adverum Biotechnologies, Inc. (NASDAQ:ADVM)TCG Crossover Management LLC decreased its holdings in shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) by 10.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,796,482 shares of the biotechnology company's stoMay 1 at 8:03 AM | marketbeat.comAdverum Biotechnologies, Inc. (ADVM) Stock ForecastsApril 30, 2025 | ca.finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVMApril 29, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVMApril 28, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVMApril 25, 2025 | globenewswire.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Major Shareholder Purchases $149,000.00 in StockApril 25, 2025 | insidertrades.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVMApril 22, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVMApril 21, 2025 | globenewswire.comChardan Capital Has Lowered Expectations for Adverum Biotechnologies (NASDAQ:ADVM) Stock PriceChardan Capital dropped their price target on shares of Adverum Biotechnologies from $40.00 to $33.00 and set a "buy" rating for the company in a research note on Thursday.April 19, 2025 | marketbeat.comRoyal Bank of Canada Lowers Adverum Biotechnologies (NASDAQ:ADVM) Price Target to $5.00Royal Bank of Canada cut their target price on Adverum Biotechnologies from $10.00 to $5.00 and set a "sector perform" rating for the company in a research note on Wednesday.April 18, 2025 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Rating of "Moderate Buy" from AnalystsShares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) have received an average recommendation of "Moderate Buy" from the six research firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and fiveApril 18, 2025 | marketbeat.comAdverum Biotechnologies (NASDAQ:ADVM) Given Buy Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Adverum Biotechnologies in a research note on Wednesday.April 18, 2025 | marketbeat.comAdverum Biotechnologies (NASDAQ:ADVM) Releases Earnings ResultsAdverum Biotechnologies (NASDAQ:ADVM - Get Free Report) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($1.96) earnings per share (EPS) for the quarter.April 17, 2025 | marketbeat.comRBC Capital Keeps Their Hold Rating on Adverum Biotechnologies (ADVM)April 17, 2025 | markets.businessinsider.comAdverum Biotechnologies sees cash runway into 2H25April 16, 2025 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Adverum Biotechnologies (ADVM)April 16, 2025 | markets.businessinsider.comADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. Fraud Investigation with the Schall Law FirmApril 15, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVMApril 14, 2025 | prnewswire.comADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. ...April 13, 2025 | gurufocus.comADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. Fraud Investigation with the Schall Law FirmApril 13, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVMApril 8, 2025 | prnewswire.comInsider Buying: Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Major Shareholder Purchases 15,209 Shares of StockAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) major shareholder Braden Michael Leonard bought 15,209 shares of the firm's stock in a transaction that occurred on Wednesday, April 2nd. The stock was bought at an average price of $4.04 per share, with a total value of $61,444.36. Following the completion of the acquisition, the insider now owns 2,757,526 shares of the company's stock, valued at $11,140,405.04. This trade represents a 0.55 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.April 5, 2025 | marketbeat.comInsider Buying: Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Major Shareholder Purchases 15,209 Shares of StockAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) major shareholder Braden Michael Leonard bought 15,209 shares of Adverum Biotechnologies stock in a transaction that occurred on Wednesday, April 2nd. The stock was bought at an average price of $4.04 per share, with a total value of $61,444.36. Following the purchase, the insider now owns 2,757,526 shares of the company's stock, valued at $11,140,405.04. This trade represents a 0.55 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.April 4, 2025 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Major Shareholder Braden Michael Leonard Buys 19,566 SharesAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) major shareholder Braden Michael Leonard acquired 19,566 shares of the firm's stock in a transaction on Monday, March 31st. The stock was purchased at an average cost of $4.38 per share, for a total transaction of $85,699.08. Following the completion of the acquisition, the insider now owns 2,742,317 shares in the company, valued at approximately $12,011,348.46. This represents a 0.72 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.April 4, 2025 | marketbeat.comAdverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 4, 2025 | globenewswire.comAdverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual ConferenceMarch 31, 2025 | globenewswire.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Major Shareholder Buys $102,851.28 in StockAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) major shareholder Braden Michael Leonard bought 20,407 shares of the stock in a transaction dated Wednesday, March 26th. The shares were acquired at an average cost of $5.04 per share, for a total transaction of $102,851.28. Following the completion of the acquisition, the insider now directly owns 125,207 shares of the company's stock, valued at approximately $631,043.28. This trade represents a 19.47 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.March 28, 2025 | marketbeat.comInsider Buying: Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Major Shareholder Acquires 20,407 Shares of StockMarch 28, 2025 | insidertrades.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Major Shareholder Braden Michael Leonard Purchases 30,600 SharesAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) major shareholder Braden Michael Leonard bought 30,600 shares of the stock in a transaction dated Thursday, March 20th. The shares were bought at an average cost of $5.61 per share, with a total value of $171,666.00. Following the completion of the purchase, the insider now directly owns 2,722,761 shares of the company's stock, valued at approximately $15,274,689.21. This trade represents a 1.14 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.March 21, 2025 | marketbeat.comInsider Buying: Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Major Shareholder Purchases 62,341 Shares of StockAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) major shareholder Braden Michael Leonard purchased 62,341 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were acquired at an average cost of $4.69 per share, with a total value of $292,379.29. Following the acquisition, the insider now directly owns 2,667,161 shares in the company, valued at approximately $12,508,985.09. The trade was a 2.39 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.March 21, 2025 | marketbeat.comBraden Michael Leonard Buys 30,600 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) StockMarch 21, 2025 | insidertrades.comRegeneron Pharmaceuticals Inc. Takes $845,000 Position in Adverum Biotechnologies, Inc. (NASDAQ:ADVM)Regeneron Pharmaceuticals Inc. purchased a new position in shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 180,909 sharesMarch 11, 2025 | marketbeat.comAdverum Biotechnologies (ADVM) to Release Earnings on MondayAdverum Biotechnologies (NASDAQ:ADVM) will be releasing earnings before the market opens on Monday, March 17, Financial Modeling Prep reports.March 10, 2025 | marketbeat.comAdverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMDMarch 4, 2025 | markets.businessinsider.comAdverum Biotechnologies initiates ARTEMIS studyMarch 4, 2025 | markets.businessinsider.comAdverum Biotechnologies (NASDAQ:ADVM) Shares Cross Below Two Hundred Day Moving Average - Here's What HappenedAdverum Biotechnologies (NASDAQ:ADVM) Share Price Passes Below Two Hundred Day Moving Average - What's Next?March 4, 2025 | marketbeat.comAdverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMDMarch 3, 2025 | globenewswire.comAdverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 28, 2025 | globenewswire.comAdverum Biotechnologies to Participate in the Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | globenewswire.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) have received an average rating of "Moderate Buy" from the six brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company.February 24, 2025 | marketbeat.com3 US Penny Stocks With Market Caps Below $400MFebruary 19, 2025 | finance.yahoo.comAdverum Biotechnologies (NASDAQ:ADVM) Share Price Crosses Below 200-Day Moving Average - Here's What HappenedAdverum Biotechnologies (NASDAQ:ADVM) Stock Price Crosses Below 200 Day Moving Average - What's Next?February 15, 2025 | marketbeat.comADVM stock touches 52-week low at $3.95 amid sharp annual declineFebruary 13, 2025 | msn.com4D Molecular’s wAMD drug is best-in-class, says RBC, sees ‘ideal’ entry pointFebruary 11, 2025 | markets.businessinsider.comAdverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | globenewswire.comADVM stock touches 52-week low at $4.01 amid market challengesFebruary 4, 2025 | msn.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy ratJanuary 30, 2025 | marketbeat.com Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address ADVM Media Mentions By Week ADVM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADVM News Sentiment▼0.220.73▲Average Medical News Sentiment ADVM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADVM Articles This Week▼72▲ADVM Articles Average Week Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LFCR News CRVS News CADL News DSGN News CDTX News ENGN News RZLT News DRUG News HUMA News PLX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADVM) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADVM Stock Free ADVM Stock Alerts